BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBTelix expands US radiopharma footprint with $250M RLS buy. Radiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of... Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
US FDA expands guidance on race, ethnicity data in trials - BioWorld
WEBJan 29, 2024 — In keeping with federal standards for classifying race and ethnicity data, the U.S. FDA issued a draft revision to broaden its 2016 guidance on the collection of such data in clinical trials.
BBO-10203 inhibits RAS-driven PI3Kα activity in tumor cells
WEBDec 27, 2023 — Researchers from Bridgebio Pharma Inc. recently presented BBO-10203, a first-in-class, orally bioavailable, covalent small-molecule candidate designed to inhibit RAS-driven PI3Kα activity without affecting glucose metabolism.
mRNA vaccine could prevent and treat HPV-related cancer
WEBApr 3, 2024 — A group of scientists at Shanghai Virogin Biotech Co. and Zhujiang Hospital in China designed a new mRNA vaccine that could prevent tumor formation associated with human papillomavirus 16 (HPV16) and also reduce its size if used as a treatment.
US-China company Triarm on a mission to democratize CAR Ts
WEBMar 26, 2024 — Triarm Therapeutics Ltd. is on a mission to democratize CAR T therapies to make them more accessible and affordable, Triarm CEO Jay Zhang told BioWorld. “Nearly half of the patients eligible for CAR T therapies still cannot get treated, and the main reason is the expense, and the second is they cannot afford to wait.
Getinge to acquire Paragonix for $477M - BioWorld
WEBAug 23, 2024 — Getinge AB agreed to acquire Paragonix Technologies Inc. for $477 million, including upfront and earn out payments. The deal marks Getinge’s entry into the global organ preservation and transportation market, a rapidly advancing field driven by rising transplant volumes, technological innovations and evolving clinical practices.
Patents | BioWorld
WEB2 days ago — Sep. 10, 2024. No Comments. New miR-124 activators have been reported in a recent Nanjing Synnocare Pharmaceutical Technology Co. Ltd. patent as potentially useful for the treatment of Alzheimer type dementia, Parkinson’s disease, Crohn’s disease, ulcerative colitis, rheumatoid arthritis, cancer and viral infections. Read More.
IBI-3001, potentially first-in-class B7-H3/EGFR bsADC with
WEBApr 9, 2024 — At the AACR meeting, Innovent Biologics Inc. discussed the discovery and preclinical evaluation of a B7-H3/EGFR bispecific antibody-drug conjugate (bsADC).
Hainan Simcere Pharmaceutical discloses CBL-B inhibitors
WEBAug 14, 2024 — Hainan Simcere Pharmaceutical Co. Ltd. has patented E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
MK-5661, a potent Nav1.8 inhibitor with promising safety and
WEBApr 4, 2024 — MK-5661, a potent Nav1.8 inhibitor with promising safety and low oral dose predictions. Discovery of novel Nav1.8 inhibitors capable of achieving high levels of target modulation at low oral doses for the potential treatment of pain was reported by Merck & Co. Inc. Strategics tend to invest in med-tech companies they are looking to acquire or ...